Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1049-1060

  Benza, Raymond L ^a   Gomberg Maitland, Mardi ^b   Frost, Adaani E ^c   Frantz, Robert P ^d   Humbert, Marc ^e   McGoon, Michael D ^d  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Prognosis; Pulmonary arterial hypertension; REVEAL; Risk calculator; Survival prediction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ARTICLE; DEMOGRAPHY; DISEASE REGISTRY; FRENCH REGISTRY; HEART ATRIUM PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAYO REGISTRY; NATIONAL HEALTH ORGANIZATION; PHC REGISTRY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVEAL; RISK; SCORING SYSTEM;

HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84870883052     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0821     Document Type: Article

References (34)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. Benza RL, Miller D P, Barst RJ, et al. An Evaluation of Long-Term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From REVEAL. Chest 2012; prepub online.
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
4. D'Alonzo GE, Barst RJ, Ay res SM, et al. Sur v ival in patients w ith primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
6. Benza RL, Miller D P, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
7. Jing Z.C, Xu X.Q, Han Z.Y. et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-379.
8. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007; 137: 510-513.
9. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
10. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
11. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.
12. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
13. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008; 83: 923-931.
14. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
15. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
16. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2011; 36: 549-555.
17. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
18. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
19. Kane GC, Maradit-Kremers H, Slusser J P, et al. Integration of clinical and he-modynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011; 139: 1285-1293.
20. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
21. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest 2011; 139: 128-137.
22. Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 2003; 24: 682-701.
23. McLaughlin V V, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010; 122: 106-108.
24. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23: 2109-2123.
25. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
26. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-2667.
27. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoe-pidemiol Drug Saf 2007; 16: 241-249.
28. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499.
29. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 34: 132-137.
30. Benza RL, Gomberg-Maitland M, Miller D P, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141: 354-362.
31. Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection for survival prediction in pulmonary arterial hypertension. Chest 2012; 141: 642-650.
32. Benza RL, Miller D P, Frantz R P, et al. Association between serial 6MWD assessments and the REVEAL PAH risk score calculator [abstract 123]. J Heart Lung Transplant 2010; 29: S46.
33. Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011; 30: 982-989.
34. Sachdev A, Villarraga HR, Frantz R P, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest 2011; 139: 1299-1309.